A population pharmacokinetic model of cabozantinib in healthy volunteers and patients with various cancer types

PURPOSE: An integrated population pharmacokinetic (popPK) model was developed to describe the pharmacokinetics (PK) of tyrosine kinase inhibitor cabozantinib in healthy volunteers (HVs) and patients with various cancer types and to identify any differences in cabozantinib PK across these populations...

Descripción completa

Detalles Bibliográficos
Autores principales: Lacy, Steven, Yang, Bei, Nielsen, Jace, Miles, Dale, Nguyen, Linh, Hutmacher, Matt
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973963/
https://www.ncbi.nlm.nih.gov/pubmed/29687244
http://dx.doi.org/10.1007/s00280-018-3581-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973963/
https://www.ncbi.nlm.nih.gov/pubmed/29687244
http://dx.doi.org/10.1007/s00280-018-3581-0

Ejemplares similares